A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1

A. E. Seif, A. Naranjo, D. L. Baker, N. J. Bunin, M. Kletzel, C. S. Kretschmar, J. M. Maris, P. W. McGrady, D. Von Allmen, S. L. Cohn, W. B. London, J. R. Park, L. R. Diller, S. A. Grupp*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Increasing treatment intensity has improved outcomes for children with neuroblastoma. We performed a pilot study in the Children's Oncology Group to assess the feasibility and toxicity of a tandem myeloablative regimen without TBI supported by autologous CD34-selected peripheral blood stem cells. Forty-one patients with high-risk neuroblastoma were enrolled; eight patients did not receive any myeloablative consolidation procedure and seven received only one. Two patients out of 41 (4.9%) experienced transplant-related mortality. CD34 selection was discontinued after subjects were enrolled due to serious viral illness. From the time of study enrollment, the overall 3-year EFS and OS were 44.8±9.6% and 59.2±9.2% (N=41). These results demonstrate that tandem transplantation in the cooperative group setting is feasible and support a randomized comparison of single vs tandem myeloablative consolidation with PBSC support for high-risk neuroblastoma.

Original languageEnglish (US)
Pages (from-to)947-952
Number of pages6
JournalBone Marrow Transplantation
Volume48
Issue number7
DOIs
StatePublished - Jul 2013

Keywords

  • Pediatric
  • hematopoietic SCT
  • neuroblastoma
  • tandem transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1'. Together they form a unique fingerprint.

Cite this